InnoSkel gets MHRA Innovation Passport

French start-up InnoSkel has been awarded an Innovation Passport under the UK Medicines and Healthcare products Regulatory Agency’s (MHRA) Innovative Licensing and Access Pathway (ILAP).

This designation will allow the privately-held firm to pursue accelerated patient access for its treatment for spondyloepiphyseal dysplasia congenita (SEDc), a type II collagen disorder.

"The passport provides the opportunity to engage with regulators, health technology assessment bodies and other partners at a pre-clinical stage"INS-101, InnoSkel’s lead gene therapy program, is being developed for the treatment of SEDc in pediatric patients, for whom there is currently no disease-modifying therapy available.